KUALA LUMPUR: Pharmaniaga Bhd
said it remains well-positioned for growth, bolstered by a resilient performance in the concession segment, significant advancements in biopharmaceuticals and strategic expansion in Indonesia.
According to the group, its concession segment continues to demonstrate strength, with a notable increase in revenue in the nine months to Sept 30, 2024.
"We anticipated further growth in 4Q24 and into 2025, as the number of active products under the Approved Product Purchase List (APPL) is expected to increase
from 655 products in 3Q24 to 832 products by the end of 2025.
"This expansion is projected to drive both sales and volume within the concession segment, reinforcing Pharmaniaga's commitment as a strategic partner to the Ministry of Health in serving the nation," it said in a filing with Bursa Malaysia.
In the third quarter ended Sept 30, 2024, Pharmaniaga recorded a net profit of RM101.03mil, as compared to a net loss of RM49.34mil in the year-ago quarter.
Revenue during the quarter was RM1.03bil against RM885.49mil previously.
Over the nine months period, the group registered a net profit of RM129.48mil on revenue of RM2.83bil as compared to a net loss of RM44.73mil on revenue of RM2.61bil.
